CD34 and Schnyder corneal dystrophy: Clinical development of gene therapy for SCD started with a first patient treated in France, with transplantation of CD34+ HSPCs transduced with the BB305 vector expressing the βA-T87Q globin at a dose of 5 × 106 cells/kg and an average vector copy number (VCN) of 1 after full myeloablative conditioning.